Bethesda, MD (Could 14, 2021) — Combining minimally invasive endoscopic sleeve gastroplasty (ESG) with the diabetes drug semaglutide can present further vital weight reduction for sufferers who will not be candidates for invasive weight-loss surgical procedure, in keeping with analysis that was chosen for presentation at Digestive Illness Week® (DDW) 2021.
“Because the worldwide weight problems charge continues to climb, so do the variety of folks looking for bariatric surgical procedure to deal with their situation,” mentioned Anna Carolina Hoff, MD, lead researcher on the examine and founder and medical director of Angioskope Brazil, São José dos Campos. “Surgical procedures are a number of the most profitable methods to assist sufferers drop a few pounds, however they will ultimately include problems. Our examine exhibits that sufferers might not need to bear invasive surgical procedure to get comparable outcomes.”
In a double-blind examine, researchers randomized 61 sufferers present process ESG into two teams with one group of 29 sufferers receiving semaglutide — an injectable glucagon-like peptide-1 receptor that has been recognized to stimulate weight reduction — starting one month after the process. One other group of 29 sufferers obtained a placebo administered with look-alike injector pens. Three sufferers have been misplaced to follow-up. Individuals have been monitored every month for physique weight and physique composition, and blood panels have been taken each three months.
Sufferers who obtained semaglutide misplaced on common 26.7 p.c of their whole physique weight in comparison with the management group, which on common misplaced 19.6 p.c of whole physique weight. The semaglutide group misplaced 86.3 p.c of their extra weight — the quantity of weight the sufferers wanted to lose to succeed in regular BMI — in comparison with 60.4 p.c for the management group. The semaglutide group additionally misplaced 12.7 p.c of their physique fats by weight in comparison with 9 p.c for the management group. Lastly, glycated hemoglobin (Hb1Ac) ranges fell 0.95 for the semaglutide group and 0.61 for the controls.
Surgical procedures, comparable to laparoscopic sleeve gastrectomy, include elevated prices and the next danger for problems, comparable to gastroesophageal reflux illness, or GERD. These surgical procedures are usually restricted to these with a BMI of at the least 35 with comorbidities, or with a BMI above 40. ESG will be carried out at an earlier stage of the illness and at a decrease BMI, so extra sufferers can get the remedy they want earlier than their illness progresses. Treating sufferers with weight problems earlier may help cut back dying and comorbidities in addition to cut back prices related to remedies for these circumstances.
“ESG has been out there to sufferers for years, nevertheless it has not all the time been as profitable as surgical choices in serving to sufferers drop a few pounds,” mentioned Dr. Hoff. “We now have a minimally invasive process that may be simply as profitable when mixed with semaglutide and will be made out there to much more folks seeking to lose a major quantity of weight.”
ESG is carried out by guiding a tool by way of the affected person’s throat and into the abdomen, the place an endoscopist makes use of sutures to make the abdomen smaller. This helps sufferers drop a few pounds by limiting the quantity they will eat. Sufferers are candidates for ESG if they’ve a BMI at or above 30, and weight loss plan and train haven’t helped them drop a few pounds, or if they don’t seem to be a candidate for surgical procedure, or don’t want to pursue surgical procedure.
The researchers warning that long run sturdiness of the remedy nonetheless must be decided.
DDW Presentation Particulars
Dr. Hoff will current knowledge from the examine, “Semaglutide in affiliation to endoscopic sleeve gastroplasty: Taking endoscopic bariatric procedures outcomes to the following stage,” summary Su548, on Sunday, Could 23, at 12:15 p.m. EDT. For extra details about featured research, in addition to a schedule of availability for featured researchers, please go to http://www.
Digestive Illness Week® (DDW) is the most important worldwide gathering of physicians, researchers and teachers within the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgical procedure. Collectively sponsored by the American Affiliation for the Research of Liver Ailments (AASLD), the American Gastroenterological Affiliation (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgical procedure of the Alimentary Tract (SSAT), DDW is a completely digital assembly from Could 21-23, 2021. The assembly showcases greater than 2,000 abstracts and tons of of lectures on the newest advances in GI analysis, medication and know-how. Extra info will be discovered at http://www.
Disclaimer: AAAS and EurekAlert! will not be answerable for the accuracy of stories releases posted to EurekAlert! by contributing establishments or for the usage of any info by way of the EurekAlert system.